Infinitum Health Announces Incorporation as a C-Corporation to Accelerate Biotechnology Innovation

Phoenix, Arizona – November, 2025 – Infinitum Health, a biotechnology company pioneering evidence-based natural therapeutics, is proud to announce its official incorporation as Infinitum Health, Inc., transitioning from a limited liability company (LLC) to a C-Corporation. This milestone marks a new chapter in the company’s growth—positioning Infinitum Health for expanded research, investment, and strategic partnerships in oncology, virology, pain, and integrative biotechnology.

“This incorporation reflects not only our evolution as a company but our deep commitment to scaling our research and impact,” said Kevin Engholdt, Founder and CEO of Infinitum Health. “We began as a purpose-driven LLC focused on creating safe, natural, and effective consumer health products. Today, as a C-Corporation, we’re building the foundation to bring our discoveries to patients worldwide.”

A Legacy of Purpose and Discovery

Founded in 2011, Infinitum Health began with a single idea: that biotechnology could harness the power of nature to support human "health forever, without limits.” Its flagship product, Infinimin®, was developed through a proprietary mathematical model guiding natural compound design and optimization. The formula has been studied in preclinical trials at leading research institutions, including the Mayo Clinic, showing statistically significant results in multiple cancer cell lines.

Over the years, the company has expanded its research and intellectual property portfolio to include:

• One issued U.S. patent: Method of Inhibiting Cancer Growth and Inhibiting Viral Infections (US 12,364,725 B2, July 2025)

• One patent pending: Method of Relieving Pain

• Three trademarks and a trade secret mathematical model guiding product innovation

  
  

Strategic Expansion Through Incorporation

Transitioning to a C-Corporation structure opens new opportunities for institutional funding, strategic partnerships, and clinical trials. Infinitum Health’s near-term focus includes:

• Advancing Phase III clinical trials in oncology, virology, and pain management.

• Expanding collaborations with global research institutions.

• Building out its biotechnology and consumer health product lines, including Infiniderm®, ReLeaf™, Ancient Cleanse™, Dragon Roast™ Coffee, and Immortalis™ Spirits.

  
  

The incorporation also reflects the company’s readiness for venture and institutional investment, aligning with its $15 million Series Seed funding target to accelerate research and commercialization

About Infinitum Health

Infinitum Health, Inc. is a biotechnology company dedicated to developing natural, evidence-based products that support health and longevity. Founded by Kevin T. Engholdt, MS, MBA, the company integrates biotechnology, data modeling, and clinical research to create innovations in oncology, virology, pain, and immune health. With products spanning nutraceuticals, topicals, and functional foods, Infinitum Health is redefining what’s possible at the intersection of nature and science.

For more information, visit: www.infinitumhealth.com